High-level consultation event
The following thought-leader pieces were commissioned by sci-com.eu
By Prof. Michel Kazatchkine, MD, (FR), Consultation Event Co-Chair & UN Secretary-General Ban-ki Moon’s Special Envoy on HIV/AIDS to Eastern Europe and Central Asia; Member of the Global Commission on Drug Policy and Former Executive Director, The Global Fund to fight AIDS, Tuberculosis & Malaria.
By Dr. Wilson Compton, MD, MPE, Consultation Event Co-Chair & Deputy Director, National Institute on Drug Abuse (NIDA), National Institutes of Health, Department of Health and Human Services, USA.
By Dr Wilson Compton, Director, Division of Epidemiology, Services & Prevention Research, US National Institute on Drug Abuse (NIDA).
By Prof. Julian Kinderlerer (SA), Consultation Event Co-Chair, President of the European Group on Ethics in Science and New Technologies (EGE) reporting to European Commission President Juncker and the European Parliament; Prof. of Intellectual Law, Cape Town University; Adviser to the South African Science Ministry; Occasional Adviser to the UN Environment Programme; UN Industrial Development Organisation; World Intellectual Property Organisation; Former Director of Institutes on Biotech Law, Ethics & Society at Delft and Sheffield Universities.
By Professor Sir Peter Gluckman (NZ), Guest Contributor: Paediatrician and Endocrinologist; Chief Science Adviser to the Prime Minister of New Zealand; Chairman, International Network on Science Advice to Governments; Co-Chair of the WHO Commission on Ending Childhood Obesity; Elected Foreign Member of the Institute of Medicine, US National Academies of Science; Fellow of the UK Academy of Medical Sciences and Fellow of the Royal Society London; University Distinguished Professor, University of Auckland; Visiting Professor, University College London; and holder of Honorary Chairs at the National University of Singapore and University of Southampton. He is also Chief Scientific Officer, Singapore Institute for Clinical Sciences; Dean Emeritus of the Faculty of Medical and Health Sciences and Director Emeritus of the Liggins Institute, University of Auckland.
By Thomas Hartung, Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA, and CAAT-Europe, University of Konstanz, Germany.
By Deborah Arnott (UK), Guest Contributor, MBA FRCP (Hon), Chief Executive, Action on Smoking & Health (ASH UK) is a well-respected public health campaigner championing greater awareness about the tobacco epidemic worldwide, while pressing for evidence-based policy measures that do not attack smokers or condemn smoking. Reporting to the Royal College of Physicians, ASH provides the secretariat for the UK’s All Party Parliamentary Group on Smoking and Health.
By Dr. Mary Baker MBE (UK), Participant, is Immediate Past President of the European Brain Council, Immediate Past President of the European Federation of Neurological Associations; Consultant to the World Health Organisation (WHO); Member of EFPIA Advisory Board and Chair of the Working Group on Parkinson’s Disease; and a member of the European Commission’s CONNECT Advisory Forum. Academic appointments include Associate Membership of the Health Services Research Unit, University of Oxford and Visiting Fellow within the Health Centre at London School of Economics (LSE).
By M.D. Kevin Bridgman (UK) Participant, is a qualified clinician with extensive pharmaceutical industry experience in both prescription and consumer healthcare. He is currently Chief Medical Officer and Director of Compliance at Nicovations Ltd, a subsidiary of British American Tobacco, developing and commercialising innovative inhaled nicotine products that meet medicines standards, for smokers wishing to reduce, replace or stop smoking.
By Andy Stonard, Consultation Event Alcohol Panel Chair is the CEO of Esprit du Bois and the Former CEO of Rugby House – Drug & Alcohol Treatment Services. He is author of A Glass Half Full: Drinking – Reducing The Harm
Professor Philippe de Witte, Head of the Laboratory of Behavioural Biology at the Université Catholique de Louvain (UCL), Belgium. He is Editor-in-Chief of Alcohol and Alcoholism and Chairman of the Advisory Board of the European Foundation for Alcohol Research. He is a former Fulbright Scholar, specialising in brain research at the US National Institutes of Health.
By Paul Skehan (IRL), Participant, Director General of spiritsEUROPE. Based in Brussels, he represents the interests of the European spirits sector and 32 national trade associations of spirits producers, as well as a group of the EU’s largest spirits producing companies, all household names. He is a passionate advocate for greater transparency about how science feeds into EU policy-making.
Call
+ 27 (0)12 841 3286
Email
info@africasciencediplomacy.org
Address
CSIR International Convention Centre, Meiring Naude Road, Brummeria, Pretoria, South Africa, 0001